<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216177</url>
  </required_header>
  <id_info>
    <org_study_id>232-003</org_study_id>
    <secondary_id>EudraCT no: 2005-001633-14</secondary_id>
    <secondary_id>Switch/HUM 05-001</secondary_id>
    <nct_id>NCT00216177</nct_id>
  </id_info>
  <brief_title>Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>Randomised, Multicenter, Open-label, Parallel-group Study Comparing Adalimumab 40 mg s.c. Eow Versus Infliximab 3 mg/kg i.v. Every 6 Weeks in Rheumatoid Arthritis Patients With Unsustainable Clinical Response to Infliximab 3 mg/kg Every 8 Weeks</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish whether RA patients with moderate to severe disease
      activity with unsustainable response to infliximab 3 mg/kg every 8 weeks have better efficacy
      with adalimumab 40 mg s.c. eow compared to infliximab 3 mg/kg i.v. every 6 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2005</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <primary_completion_date type="Anticipated">January 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients achieving combined good or moderate EULAR responses at week 24</measure>
    <time_frame>six months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR20/50/70 response at week 2, 6, 12, 18 and 24</measure>
    <time_frame>six months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Remicade</description>
    <other_name>remicade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Humira</description>
    <other_name>Humira</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ACR criteria fulfilled,DAS28-3(CRP &gt; 3.2

          -  &gt; 6 months prior treatment with infliximab 3 mg/kg i.v. every 8 week with initial
             response

          -  Fading clinical response to infliximab

          -  Negative pregnancy test (women with childbearing potential)

          -  Use of reliable method of contraception (women with childbearing potential)

          -  Informed consent

        Exclusion Criteria:

          -  Age less than 18 years

          -  Lack of co-operability

          -  Positive serology for hepatitis B or C

          -  History of positive HIV status

          -  History of TB or untreated latent TB

          -  Histoplasmosis or Listeriosis

          -  Pregnancy or breastfeeding

          -  Persistent or recurrent infections

          -  History of cancer

          -  Uncontrolled diabetes

          -  Ischaemic heart disease

          -  Congestive heart failure (NYHA 3-4)

          -  Active inflammatory bowel disease

          -  Recent stroke (within 3 months)

          -  History of or current inflammatory joint disease other than RA

          -  Previous diagnosis or signs of central nervous system demyelinating disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henrik Skjodt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Henrik Skjodt, MD, PhD</last_name>
    <phone>3632 3311</phone>
    <email>hskj@dadlnet.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mikkel Ostergaard, MD, DMedSci</last_name>
    <email>mo@dadlnet.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Copenhagen</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Skjodt, MD, PhD</last_name>
      <email>hskj@dadlnet.dk</email>
    </contact>
    <contact_backup>
      <last_name>Mikkel Ostergaard, MD, DMedSci</last_name>
      <email>mo@dadlnet.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karsten , Asmussen</last_name>
      <email>drasmus@post8.tele.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gentofte Amtssygehus</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ole Rintek, MD, DMedSci</last_name>
      <email>rintek@dadlnet.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Glostrup Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gorm Thamsborg, MD, DMedSci</last_name>
      <email>goth@glostruphosp.kbhamt.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Baslund, MD, PhD</last_name>
      <email>baslund@rh.dk</email>
    </contact>
    <contact_backup>
      <last_name>Annette Hansen, MD, PhD</last_name>
      <email>d263249@inet.uni2.dk</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Graasten Gigthospital</name>
      <address>
        <city>Graasten</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lis S Andersen, MD, PhD</last_name>
      <email>lsandersen@gigtforeningen.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>August 17, 2009</last_update_submitted>
  <last_update_submitted_qc>August 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2009</last_update_posted>
  <responsible_party>
    <name_title>Henrik Skjodt</name_title>
    <organization>Hvidovre Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

